|
|
Please use your "back" browser to return to the Main/Navigation page or click here: http://rimadyldeath.com.
If you are on this page, you are probably already familiar with what's currently taking place in the drug industry
Another "industry" has now jumped onto the bandwagon in the middle of this "health/safety" crisis. Is it "drumming up business" or "drumming up DEATH"?
YOU be the judge, after all it's only YOUR life and that of your loved ones that's at stake!
Tough Times Ahead for Cox-2 Inhibitors; Demonstrating Safety is Crucial
PALO ALTO, Calif.--(BUSINESS WIRE)----With the recent recall of Vioxx, a critical challenge facing the Cox-2 inhibitor markets in the United States is the need to conclusively demonstrate the safety of these drugs in long-term use.
New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Vioxx Recall: Revenue Analysis and Impact on Cox-2 Inhibitor Markets, reveals through its pessimistic forecasts that this market generated revenue of $3.6 billion in 2004. Total market revenues expect to decrease to $3.13 billion in 2010.
If you are interested in a virtual brochure, which provides manufacturers, end-users and other industry participants an overview of the latest analysis of the Vioxx Recall: Revenue Analysis and Impact on Cox-2 Inhibitor Markets - then send an email to Danielle White - Corporate Communications at dwhite@frost.com with the following information: your full name, company name, title, telephone number, fax number, and email. Upon receipt of the above information, an overview will be sent to you via e-mail.
The drug was voluntarily recalled after data from a clinical trial revealed those it-increased patients' risks of getting heart attacks and strokes. Proving the safety of other Cox-2 inhibitors in long-term use is, therefore, likely to be a difficult task.
"Post recall, gaining the approval of the Food and Drug Administration (FDA) for new Cox-2 inhibitors is likely to be a long-drawn out process," says Frost & Sullivan Research Analyst Elisa Perez. "The FDA may even require additional information that will prolong the return on investment (ROI) for these products."
Extensive clinical trials are necessary to demonstrate the safety of using Cox-2 inhibitors over a prolonged period of time. While these trials will involve additional expenses, they are essential if companies hope to gain the required FDA approval and successfully penetrate the market.
The market also faces the challenge of getting physicians and patients to accept these drugs for use as pain management therapies.
"Physicians' reluctance to prescribe Cox-2 inhibitors for pain therapy is increasing," remarks Perez. "A growing amount of data - suggesting that other Cox-2 inhibitors may also carry the risk of cardiovascular adverse effects - is likely to further hurt this market as physicians and patients look to over-the-counter (OTC) products or traditional non-steroidal anti-inflammatory drugs (NSAIDs) for pain management."
." Removing the stigma associated with the adverse side effects of Vioxx, and potentially other Cox-2 inhibitors as well, will require companies to adopt aggressive marketing strategies targeted at physicians as well as patients. Physician education will help in increasing their prescriptions of these therapies, which in turn will make patients more amenable to using them.
"With the recall of Vioxx having impacted not only the Cox-2 inhibitor markets, but also the pharmaceuticals industry as a whole, patient and physician education is critical," remarks Perez. "Pharmaceutical companies should work closely with the FDA to determine the best strategy in the event of recall of a drug. Clinical trials to ensure long-term efficacy and safety are very important for the success of a drug."
Vioxx Recall: Revenue Analysis and Impact on Cox-2 Inhibitor Markets, part of the Pharmaceuticals (9611) subscription, which also includes market insights on Pharmaceutical Strategic Snapshots (9651), analyzes the impact of recall of the drug, Vioxx, on the Cox-2 inhibitor markets. This thorough analysis includes physicians' perspectives that are expected to give pharmaceutical companies a new depth of information on measures to counter the effects of recall. The research discusses the impact of the recall in terms of revenue and patient forecasts and physicians' past and future prescription trends. Executive summaries and interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. Its advisory expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities for clients. While serving clientele ranging from virtually every Global 1000 to emerging companies, Frost & Sullivan's comprehensive industry coverage includes a global perspective of all vertical and horizontal industries. Its unique coverage combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com
Vioxx Recall: Revenue Analysis and Impact on Cox-2 Inhibitor Markets
F135
Keywords in this release: Cox-2 inhibitors, Vioxx, United States, Food and Drug Administration, FDA, over-the-counter products, OTC, traditional non-steroidal anti-inflammatory drugs, NSAIDs, research, information, market, trends, technology, service, forecast
Frost & Sullivan North America Danielle White, 210-247-2403 fax: 210-348-1003 dwhite@frost.com or Europe Katja Feick, +44 (0) 20 7915 7856 fax: +44 (0) 20 7730 3343 katja.feick@frost.com or Asia Pacific Radhika Menon Theodore, +91 44 24314263, ext. 312 fax: +91 44 24314264 rmtheodore@frost.com http://www.frost.com
12/15/2004 07:45 ET
and here is how it works:
One of our account executives will also be in touch with you soon to provide details on how you can acquire the entire document.
Thanks,
Danielle White
Corporate Communications, Healthcare
North America Team Leader
Frost & Sullivan
http://www.frost.com/
t) 210-247-2403
f) 210-348-1003
e) dwhite@frost.com
Ahhhhhh . . . the power of advertising - no matter how inappropriate:
Ginger Sanchez, we have an important message concerning your veterinarian.
Your veterinarian in is listed in the PetsUnlimited.com veterinary directory but some of their information is incomplete.
Please call and remind your veterinarian that their information is incomplete in the PetsUnlimited.com veterinary directory, which is searched more than 17,000 times daily.
You can find their phone number here: Find Your Vet
They are missing their hours of operation, emergency hours, alternate emergency phone numbers, the names and bio's of all their care professionals, weekly pet tips, and other important information that you and new potential customers want and need.
Don't forget to make sure you have chosen your veterinarian in your PetsUnlimited.com profile. Simply log into your profile and click on the Manage My Veterinarian Options link.
Also, be sure to use the veterinary appointment reminder feature so you don't miss your next appointment. This feature is available from your PetsUnlimited.com profile page.
Sincerely,
Member Services
PetsUnlimited.com Inc.
http://www.petsunlimited.com
Do not reply to this email as we are unable to receive email at this address.
You have received this message as a member of PetsUnlimited.com and in compliance with our terms of service, user agreement, and all applicable laws.
Please see our privacy policy and profile preferences for more information or to update your email preferences.
You can log into your profile here
PetsUnlimited.com
Reston, VA 20195
. 
May my beloved partner ROMI rest in peace - no matter wherever her bits and pieces/frozen carcass may be held hostage.
[what's in YOUR "urn" ?]
bravenet.com